Search

Displaying results 1321 - 1330 of 10000 in total
  1. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

    Products: MOXONIDINA EG, Normohex 0,2 mg - Filmtabletten
  2. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [propranolol]), all of which can be associated with significant adverse effects. … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

    Products: AQUIPTA® 10 MG, AQUIPTA® 60 MG
  3. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme.

    Products: PULMOZYME 2.500 E./2,5 ml - Lösung für einen Vernebler, PULMOZYME 2.5 MG/2.5 ML İNHALASYON ÇÖZELTİSİ, 30 ADET
  4. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils. … [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction.

    Products: FASENRA 30 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, Fasenra 30 mg solution for injection in pre-filled syringe
  5. Drug

    Pyritinol

    go.drugbank.com/drugs/DB13084
    Investigational

    Pyritinol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

    Products: ENCEFABOL 100 MG, ENCEFABOL 200 MG
  6. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and

    Synonyms: (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247Products: NGENLA 24 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, NGENLA 60 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET
  7. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    It is adminstrated as direct intrathecal injection. … An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.

    Products: Spinraza 12 mg Solution for Injection, SPINRAZA ®12 MG SOLUCION INYECTABLE
  8. Drug

    Phenothrin

    go.drugbank.com/drugs/DB13717
    Investigational

    Products: ANTI-BIT 408 MG/100 ML ŞAMPUAN, 100 ML, ANTI-BIT 408 MG/100 ML ŞAMPUAN, 150 ML
  9. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    ; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [FDA Label]. … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

    Synonyms: Flavivirus yellow fever virus 17D-204 whole, Yellow fever virus strain 17D-204 live antigenProducts: STAMARIL 0,5 ML IM/SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON VE ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET, STAMARIL 0,5 ML IM/SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON VE ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  10. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228423, A228758] As a result of its anticholinergic effects, scopolamine is being investigated for diverse therapeutic applications; currently, it is approved for the prevention of nausea and vomiting

    Mixtures: Me-PB-Hyos, Me-PB-HyosProducts: DBL HYOSCINE INJECTION BP 400 mcg/ml